The instant disclosure provides methods of multi-assay processing and multi-assay analysis. Such multi-assay processing and analysis pertain to automated detection of target nucleic acids, e.g., as performed in the clinical setting for diagnostic purposes. Also provided are common assay timing protocols derived from a variety of individual nucleic acid amplification and analysis protocols and modified to prevent resource contention. The instant disclosure also provides systems and devices for practicing the methods as described herein.

The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the spike protein of SARS-CoV-2 and methods of making and selecting the same. The antibodies can be used, for example, in prophylaxis, post-exposure prophylaxis, or treatment of SARS-CoV-2 infection. The antibodies can also be used to detect SARS-CoV-2 infection in subject.

Inventions herein described relate to methods, devices and kits for detecting viral infections, particularly COVID-19 infections by the SARs-CoV2 corona virus. Various aspects of the inventions relate to serological antibody tests, particularly those that reduce false positive. Additionally, various aspects relate to serological detection of acute phase immune responses and distinguishing them from later phase response. Additional aspects relate to detection of antibodies indicative of natural COVID-19 virus infection even if the sample is from a vaccinated individual.

A method of gatekeeping at an event includes providing a wearable electronic device including a processor, a memory, at least one biometric sensor and an indicator, validating the identity of an individual through the at least one biometric sensor, and confirming at least one criteria for entry, the criteria including, for the example of a virus, at least one of (1) the presence of antibodies corresponding to a virus, (2) a record of vaccination, or (3) a recent negative test for the virus within a predetermined period of time, signaling the condition of the individual via the indicator, presenting the indicator at a checkpoint, and admitting or refusing entry to the individual based on the indicator.

The invention relates to the field of veterinary medicine. The invention provides an immunogenic composition, comprising a hemagglutinin protein of avian influenza virus H5 subtype. Also provided is a method of differentiating animals naturally infected with AIV from animals vaccinated with the immunogenic composition of the invention. The immunogenic composition of the invention can provide a broader, more effective, long-lasting and early onset protection on poultry.

Disclosed herein are methods for analyzing for or detecting the presence of non-antibody inhibitors and/or enhancers of adeno-associated virus (AAV) vector cell transduction in a biological sample from a subject. Also disclosed herein are methods for analyzing for, or detecting the presence of, AAV binding antibodies that inhibit, reduce or decrease AAV vector cell transduction in a biological sample from a subject. The methods rely, in part, on the use of empty capsid AAV particles to absorb AAV binding antibodies, to detect enhancers or inhibitors of AAV vector cell transduction, when present, in a biological sample analyzed for AAV neutralizing antibodies (NAbs).

Provided herein are diagnostic methods, devices and kits for detecting neutralizing antibodies to SARS-CoV-2.

A electrochemical detection cell for rapid detection of viruses in a mucous sample. The detection cell has a potentiostat, a working electrode, a counter electrode, and electrolyte. When the mucous sample is dissolved in the electrolyte the detection cell is capable of measuring the presence of a specific virus that was present in the mucous sample.

The present invention provides a method for rapid, highly specific and sensitive detection and quantification of a virus by observing viral substrate binding to its host receptor protein. The invention also provides a method for rapid, highly specific and sensitive detection and quantification of a virus in an individual suspected of being infected with a virus. The invention further provides a test kit for rapid, highly specific and sensitive point-of-care detection of a virus in an individual. The viruses and their host receptor proteins that can rapidly be detected include SARS-CoV-2 and its host receptor protein ACE2. The surprisingly rapid, specific, sensitive method and kit of the invention provide a point-of care test capable of diagnosing individuals suffering from COVID-19 by observation of a color change in the assay, which color change occurs in about five minutes, and which test can be completed by a user in about 60 minutes.

Antibiotics (Abx) are the worlds most misused drugs. Antibiotics misuse occurs when the drug is administered in case of a non-bacterial infection (such as a viral infection) for which it is ineffective. Overall, it is estimated that 40-70% of the worldwide Abx courses are mis-prescribed. The financial and health consequences of Abx over-prescription include the direct cost of the drugs, as well as the indirect costs of their side effects, which are estimated at >$15 billion annually. Furthermore, over-prescription directly causes the emergence of Abx-resistant strains of bacteria, which are recognized as one of the major threats to public health today. This generates an immediate need for reliable diagnostics to assist physicians in correct Abx prescription, especially at the point-of-care (POC) where most Abx are prescribed. Accordingly, some aspects of the present invention provide methods using biomarkers for rapidly detecting the source of infection and administrating the appropriate treatment.